NCT02661854Unknown2 期
Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract
Inmunotek S.L.28 个研究点 分布在 1 个国家目标入组 186 人开始时间: 2016年6月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 186
- 试验地点
- 28
- 主要终点
- Concentration required to elicit a positive response after nasal provocation test (NPT)
研究概览
简要总结
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy
详细描述
Double blind placebo-controlled study. The subjects will receive medication during 4 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis /rhinoconjunctivitis, with or without moderate asthma, due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae allergy
- •Subjects with a positive skin prick-test (wheal sixe >6 mm diameter)
- •Specific immunoglobulin E against house dust mites >10 kU/L and whose determination does not exceed 6 months prior to the inclusion visit
- •Age between 12 and 65 years
- •Both genders
- •Subjects capable of giving informed consent
- •Subjects capable of complying with the dosing regimen
- •Subjects that have not received immunotherapy in the last 5 years
- •Subjects presenting sensitization to another aeroallergens, but that is considered clinically not relevant or no clinical interference with the nasal provocation test.
排除标准
- •Subjects outside of the age range.
- •Subjects who have previously received immunotherapy for the treatment of the allergic rhinitis/rhinoconjunctivitis due to mites and other allergens in the last 5 years.
- •Subjects that immunotherapy may be an absolute contraindication according to the criteria of the immunotherapy Committee of the Spanish society of Allergy and Clinical Immunology, and of the European Allergy and Clinical Immunology Immunotherapy Subcommittee may also include.
- •Subjects with important symptoms of rhinoconjunctivitis /bronchial asthma in which the suspension of the systemic antihistamine treatment is contraindicated.
- •Subjects with persistent severe or not controlled asthma , with a forced expiratory volume (FEV) < 70 respect to the reference value in spite of the appropriate pharmacological treatment at the time of the inclusion in the trial.
- •Subjects that have required oral corticosteroids in the 12 weeks previous to the inclusion in the trial.
- •Subjects that have previously submitted a serious secondary reaction during the skin prick test
- •Subjects in treatment with beta blockers.
- •Unstable subjects from the clinical point of view (respiratory infection, febrile, acute urticaria, etc.) at the time of the inclusion in the clinical trial
- •Subject with chronic urticaria in the last 2 years or hereditary angioedema.
- •Subjects that have some pathology (hyperthyroidism, hypertension, heart disease, etc.) is contraindicated.
- •Subjects with any other disease not associated with the rhinitis/rhinoconjunctivitis, but of potential severity and that could interfere with treatment and follow-up (epilepsy, psychomotor deterioration, diabetes, malformations, multi-operated, kidney diseases,...).
- •Subjects with autoimmune disease (lupus, thyroiditis, etc.), tumor or with diagnosis of immunodeficiency diseases.
- •Subject whose status prevents him from providing cooperation and or which present severe psychiatric disorders.
- •Subject with known allergy to other components of the vaccine different from mites allergen extract.
- •Subjects with lower airway diseases other than asthma such as emphysema or bronchiectasis.
- •Direct investigator's relatives.
- •Pregnant or women at risk of pregnancy and breastfeeding women.
结局指标
主要结局
Concentration required to elicit a positive response after nasal provocation test (NPT)
时间窗: 4 months
Change in the threshold concentration of mite allergen extract, measured in Histamine Equivalent Prick per ml (HEP/ml), needed to trigger a positive response after nasal provocation test (NPT) assessed by acoustic rhinometry. This will be compared between the beginning and end of the trial and among active groups and placebo.
次要结局
- Dose finding skin prick test(4 months)
- Number of participants with treatment-related adverse events as assessed by MM09-SIT-013(4 months)
研究者
研究点 (28)
Loading locations...
相似试验
已完成
2 期
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen AllergyRhinoconjunctivitisRhinitisNCT02654223Inmunotek S.L.180
终止
3 期
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)Allergic Fungal RhinosinusitisNCT05545072Emory University5
已完成
3 期
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess SafetyBilateral Nasal PolyposisNCT01622569Optinose US Inc.323
已完成
2 期
A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate AsthmaAsthmaNCT01383499Boehringer Ingelheim101
已完成
3 期
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional DeviceBilateral Nasal PolyposisNCT01624662Optinose US Inc.323